Pralsetinib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 100 mg
Reference Brands: Gavreto (USA/EU)
Category: Oncology Cancer Care
Pralsetinib is a selective RET (rearranged during transfection) kinase inhibitor used to treat cancers that harbor RET gene fusions or mutations. It is administered orally and represents a targeted therapy for certain non-small cell lung cancers and thyroid cancers with RET alterations. Pralsetinib is available in Capsules and strengths such as 100 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Pralsetinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Pralsetinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Pralsetinib is used for the treatment of non-small cell lung cancer (NSCLC) and thyroid cancers that have a rearranged during transfection (RET) gene alteration. It works as a selective RET kinase inhibitor, blocking the activity of abnormal RET proteins that drive cancer cell growth.
Pralsetinib is made from the active ingredient pralsetinib, a small-molecule tyrosine kinase inhibitor specifically designed to target RET fusion–positive or RET-mutant cancers.
The trade name of Pralsetinib is Gavreto.
Pralsetinib (Gavreto) is developed and marketed by Blueprint Medicines in collaboration with Genentech (a member of the Roche Group).
The generic name is Pralsetinib.
The brand name is Gavreto.
Pralsetinib is manufactured in the United States and Switzerland by Blueprint Medicines and Roche facilities following international regulatory standards for oncology drugs.
Related Products
Momelotinib
Strength:
100 mg, 150 mg, 200 mg
Form: Tablets
Reference Brands: Ojjaara (USA)
View Details
Nirogacestat
Strength:
50 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View Details
Nintedanib
Strength:
100 mg, 150 mg
Form: Capsules
Reference Brands: Ofev (USA, EU), Vargatef (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
